reason report
surf keytruda wave initi coverag op
bottom line initi coverag outperform
rate price target base dcf analysi revenu
use wacc account net cash
revenu base output proprietari immuno-oncolog
industri analyt ionian platform simul entir io
industri pipelin along blend model consensu estim
program outsid oncolog in-depth analysi merck
address follow topic present
overview valuat risk page includ keytruda
near-term catalyst page domin upcom trial
readout keytruda rival checkpoint inhibitor
keytruda path market leadership page discuss
valu driver franchis mrk aggress develop
strategi approv yield signific opportun remain
earlier line indic amen single-ag
checkpoint-inhibit challeng ahead maintain market
leadership effort undertaken mitig competit
scientif risk
busi area page discuss dynam
therapeut area outsid oncolog expect futur revenu
team approach page overview ionian
net debt total capit
dcf
year price history/av daili volume mil
compani inform svb leerink llc research
revenu present ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
mrk fortun tie keytruda sale trial readout primari
driver share price mrk earli all-in bet solid clinic commerci execut
establish deep competit platform-moat believ investor underappreci
potenti long-term divers keytruda revenu come expans earlier
line addit tumor type price increas return mrk aggress
strategi explor collabor pursu partnership acquisit promis
keytruda add-on approach extend keytruda competit moat life-cycle beyond patent-
life flip side believ investor overli worri price disrupt
view exceedingli unlik event given keytruda competit moat expect
continu growth vaccin gardasil pediatr vaccin long-term prospect
stabl given high barrier brand gener entri mrk pipelin asset
see potenti disrupt islatravir hiv extend dose prep well
opportun show industry-lead market-shap gefapix
price target base dcf use wacc account
net cash project revenu gener rang outcom keytruda
mrk io asset deriv mont carlo simul entir io industri pipelin
develop path iter model growth vaccin hiv
franchis consensu estim vertic
increment scientif innov io may continu prove difficult initi anti-
fail pursu most-promis add-on therapi bd competitor reli
price reimburs relat risk
us legisl affect drug price propos price model risk
commerci pharma keytruda exposur medicar part could make particularli
us health-system reform oncolog model remov practic incent prefer
high-volum high-reb option major leg keytruda competit moat
risk reimburs enhanc oversea re-negoti drug switch
routin practic low-cost local altern china could drive price one
daina graybosch ph certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
